Last reviewed · How we verify
rVSV∆G-ZEBOV-GP
A recombinant vesicular stomatitis virus vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and attack Ebola virus.
A recombinant vesicular stomatitis virus vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and attack Ebola virus. Used for Ebola virus disease prevention (marketed as Ervebo).
At a glance
| Generic name | rVSV∆G-ZEBOV-GP |
|---|---|
| Also known as | Ervebo |
| Sponsor | University of Birmingham |
| Drug class | Live attenuated viral vector vaccine |
| Target | Zaire ebolavirus glycoprotein (EBOV-GP) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
rVSV∆G-ZEBOV-GP is a live attenuated viral vector vaccine in which the glycoprotein gene of vesicular stomatitis virus (VSV) is replaced with the glycoprotein gene from Zaire ebolavirus (ZEBOV). This allows the vaccine to stimulate both cellular and humoral immune responses against Ebola virus without causing VSV disease. The vaccine triggers production of antibodies and T-cell responses specific to Ebola glycoprotein, providing protection against Ebola virus infection.
Approved indications
- Ebola virus disease prevention (marketed as Ervebo)
Common side effects
- Myalgia
- Fatigue
- Headache
- Fever
- Injection site reactions
Key clinical trials
- Immunology of Ebola Vaccine (PHASE2)
- EBOla Post-Exposure Prophylaxis (PHASE3)
- Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure (PHASE2)
- Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure (PHASE3)
- A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects (PHASE1)
- Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses (PHASE4)
- Prophylaxis Vaccine Antibodies Ebola (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rVSV∆G-ZEBOV-GP CI brief — competitive landscape report
- rVSV∆G-ZEBOV-GP updates RSS · CI watch RSS
- University of Birmingham portfolio CI